BBP-418, Potential LGMD2i Therapy in Phase 2 Trial, on FDA Fast Track

BBP-418, Potential LGMD2i Therapy in Phase 2 Trial, on FDA Fast Track

306170

BBP-418, Potential LGMD2i Therapy in Phase 2 Trial, on FDA Fast Track

BBP-418, an investigational disease-modifying medication that aims to improve muscle strength and function in people with limb-girdle muscular dystrophy type 2i (LGMD2i), has been given fast track designation by the U.S. Food and Drug Administration (FDA). This designation aims to facilitate and speed the development and regulatory review of  treatments with the potential to fill an unmet medical need for people with serious conditions. If approved, BBP-418 — which is now in clinical testing in patients…

You must be logged in to read/download the full post.